Cocrystal Pharma, Inc.COCPNASDAQ
Loading
EPS Growth Under PressureDecelerating
Percentile Rank49
3Y CAGR-61.5%
5Y CAGR-30.1%
Year-over-Year Change
Year-over-year earnings per share growth rate
3Y CAGR
-61.5%/yr
Quarterly compound
5Y CAGR
-30.1%/yr
Recent deceleration
Percentile
P49
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
3 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 5.00% |
| Q2 2025 | 13.04% |
| Q1 2025 | 28.13% |
| Q4 2024 | 34.69% |
| Q3 2024 | 7.55% |
| Q2 2024 | -35.90% |
| Q1 2024 | 11.36% |
| Q4 2023 | -7.32% |
| Q3 2023 | 0.00% |
| Q2 2023 | 36.92% |
| Q1 2023 | -18.18% |
| Q4 2022 | 21.43% |
| Q3 2022 | 87.39% |
| Q2 2022 | -967.31% |
| Q1 2022 | -1.96% |
| Q4 2021 | -4.08% |
| Q3 2021 | 7.55% |
| Q2 2021 | -15.22% |
| Q1 2021 | -48.39% |
| Q4 2020 | 44.64% |
| Q3 2020 | 30.00% |
| Q2 2020 | -40.35% |
| Q1 2020 | 95.86% |
| Q4 2019 | -1926.47% |
| Q3 2019 | -19.30% |
| Q2 2019 | -147.50% |
| Q1 2019 | 106.76% |
| Q4 2018 | -2265.33% |
| Q3 2018 | -29.31% |
| Q2 2018 | 23.68% |
| Q1 2018 | -129.69% |
| Q4 2017 | 328.57% |
| Q3 2017 | -124.00% |
| Q2 2017 | 60.94% |
| Q1 2017 | 96.14% |
| Q4 2016 | -3353.13% |
| Q3 2016 | 41.82% |
| Q2 2016 | 20.29% |
| Q1 2016 | 86.89% |
| Q4 2015 | -5973.08% |